HK1038025A1 - Novel anti-diabetic peptides - Google Patents
Novel anti-diabetic peptidesInfo
- Publication number
- HK1038025A1 HK1038025A1 HK01108592A HK01108592A HK1038025A1 HK 1038025 A1 HK1038025 A1 HK 1038025A1 HK 01108592 A HK01108592 A HK 01108592A HK 01108592 A HK01108592 A HK 01108592A HK 1038025 A1 HK1038025 A1 HK 1038025A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- diabetes
- type
- compounds
- treating
- activities
- Prior art date
Links
- 230000003178 anti-diabetic effect Effects 0.000 title 1
- 239000003472 antidiabetic agent Substances 0.000 title 1
- 102000004196 processed proteins & peptides Human genes 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 4
- 102000055006 Calcitonin Human genes 0.000 abstract 2
- 108060001064 Calcitonin Proteins 0.000 abstract 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 abstract 2
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 abstract 2
- 229960004015 calcitonin Drugs 0.000 abstract 2
- 230000000694 effects Effects 0.000 abstract 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 2
- 229940127438 Amylin Agonists Drugs 0.000 abstract 1
- 102000036770 Islet Amyloid Polypeptide Human genes 0.000 abstract 1
- 108010041872 Islet Amyloid Polypeptide Proteins 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 239000000556 agonist Substances 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 239000000446 fuel Substances 0.000 abstract 1
- 230000005176 gastrointestinal motility Effects 0.000 abstract 1
- 230000004060 metabolic process Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000001105 regulatory effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Zoology (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Toxicology (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/138,056 US6087334A (en) | 1998-08-21 | 1998-08-21 | Anti-diabetic peptides |
PCT/US1999/017918 WO2000011029A2 (en) | 1998-08-21 | 1999-08-09 | Novel anti-diabetic peptides |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1038025A1 true HK1038025A1 (en) | 2002-03-01 |
Family
ID=22480238
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK01108592A HK1038025A1 (en) | 1998-08-21 | 2001-12-06 | Novel anti-diabetic peptides |
Country Status (10)
Country | Link |
---|---|
US (1) | US6087334A (de) |
EP (1) | EP1104438B1 (de) |
JP (1) | JP2002523424A (de) |
AT (1) | ATE354590T1 (de) |
AU (1) | AU766545B2 (de) |
CA (1) | CA2337971C (de) |
DE (1) | DE69935229T2 (de) |
ES (1) | ES2283127T3 (de) |
HK (1) | HK1038025A1 (de) |
WO (1) | WO2000011029A2 (de) |
Families Citing this family (56)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6143718A (en) | 1995-06-07 | 2000-11-07 | Amylin Pharmaceuticals, Inc. | Treatment of Type II diabetes mellutis with amylin agonists |
US9006175B2 (en) | 1999-06-29 | 2015-04-14 | Mannkind Corporation | Potentiation of glucose elimination |
AU2001293557A1 (en) * | 2000-09-19 | 2002-04-02 | University Of Toronto | New inhibitors of iapp fibril formation and uses thereof |
ES2316757T3 (es) * | 2002-01-08 | 2009-04-16 | Amylin Pharmaceuticals, Inc. | Uso de agonistas de amilina para modular trigliceridos. |
ES2300568T3 (es) | 2002-03-20 | 2008-06-16 | Mannkind Corporation | Aparato de inhalacion. |
US20080260838A1 (en) * | 2003-08-01 | 2008-10-23 | Mannkind Corporation | Glucagon-like peptide 1 (glp-1) pharmaceutical formulations |
BRPI0507623A (pt) | 2004-02-11 | 2007-07-03 | Amylin Pharmaceuticals Inc | peptìdeos da famìlia da amilina e métodos para prepará-los e empregá-los |
US7399744B2 (en) * | 2004-03-04 | 2008-07-15 | Amylin Pharmaceuticals, Inc. | Methods for affecting body composition |
CA2575692C (en) | 2004-08-20 | 2014-10-14 | Mannkind Corporation | Catalysis of diketopiperazine synthesis |
BR122019022692B1 (pt) | 2004-08-23 | 2023-01-10 | Mannkind Corporation | Composição terapêutica em pó seco contendo dicetopiperazina, pelo menos um tipo de cátion e um agente biologicamente ativo |
KR20070083815A (ko) * | 2004-10-26 | 2007-08-24 | 론자 아게 | 고체상 합성에서 s-알킬-술페닐 보호기 |
US7759312B2 (en) * | 2005-03-11 | 2010-07-20 | Endo Pharmaceuticals Solutions Inc. | Delivery of dry formulations of octreotide |
US7452868B2 (en) * | 2005-03-11 | 2008-11-18 | Indevus Pharmaceuticals, Inc. | Controlled release formulations of octreotide |
ES2330671T3 (es) | 2005-03-31 | 2009-12-14 | Amylin Pharmaceuticals, Inc. | Amilina y agonistas de amilina para el tratamiento de enfermedades y trastornos psiquiatricos. |
HUE028691T2 (en) | 2005-09-14 | 2016-12-28 | Mannkind Corp | A method for formulating a drug based on increasing the affinity of crystalline microparticle surfaces towards active ingredients |
EP1986679B1 (de) | 2006-02-22 | 2017-10-25 | MannKind Corporation | Verfahren zur verbesserung der pharmazeutischen eigenschaften von mikropartikeln mit diketopiperazin und einem wirkstoff |
US20090181890A1 (en) * | 2006-03-31 | 2009-07-16 | Amylin Pharmaceuticals , Inc. | Amylin and Amylin Agonists for Treating Psychiatric Diseases and Disorders |
WO2008097536A2 (en) | 2007-02-05 | 2008-08-14 | Amylin Pharmaceuticals, Inc. | Compositions and methods for treating psychiatric diseases and disorders |
JP2011500850A (ja) * | 2007-10-24 | 2011-01-06 | マンカインド コーポレイション | Glp−1による副作用を防止する方法 |
US8485180B2 (en) | 2008-06-13 | 2013-07-16 | Mannkind Corporation | Dry powder drug delivery system |
AR072114A1 (es) | 2008-06-13 | 2010-08-04 | Mannkind Corp | Un inhalador de polvo seco y sistema para suministro de farmacos |
BRPI0914308B8 (pt) | 2008-06-20 | 2021-06-22 | Mannkind Corp | sistema de inalação |
JP5536053B2 (ja) * | 2008-06-25 | 2014-07-02 | エンド ファーマスーティカルズ ソリューションズ インコーポレイテッド. | 離型剤を有するオクトレオチドインプラント |
WO2009158412A2 (en) * | 2008-06-25 | 2009-12-30 | Endo Pharmaceuticals Solutions Inc. | Sustained delivery of exenatide and other polypeptides |
TWI614024B (zh) | 2008-08-11 | 2018-02-11 | 曼凱公司 | 超快起作用胰島素之用途 |
US8314106B2 (en) | 2008-12-29 | 2012-11-20 | Mannkind Corporation | Substituted diketopiperazine analogs for use as drug delivery agents |
CA2754595C (en) | 2009-03-11 | 2017-06-27 | Mannkind Corporation | Apparatus, system and method for measuring resistance of an inhaler |
NZ595021A (en) * | 2009-03-12 | 2013-04-26 | Nordic Bioscience As | Treatment of diabetes and metabolic syndrome with enteral formulations of calcitonin peptides or calcitonin receptor agonists |
KR101875969B1 (ko) | 2009-06-12 | 2018-07-06 | 맨카인드 코포레이션 | 한정된 비표면적을 갖는 디케토피페라진 마이크로입자 |
EP2496295A1 (de) | 2009-11-03 | 2012-09-12 | MannKind Corporation | Vorrichtung und verfahren zur simulation von einatmungsanstrengungen |
RU2571331C1 (ru) | 2010-06-21 | 2015-12-20 | Маннкайнд Корпорейшн | Системы и способы доставки сухих порошковых лекарств |
JP6133270B2 (ja) | 2011-04-01 | 2017-05-24 | マンカインド コーポレイション | 薬剤カートリッジのためのブリスター包装 |
WO2012174472A1 (en) | 2011-06-17 | 2012-12-20 | Mannkind Corporation | High capacity diketopiperazine microparticles |
JP6018640B2 (ja) | 2011-10-24 | 2016-11-02 | マンカインド コーポレイション | 疼痛を緩和するのに有効な鎮痛組成物並びに当該組成物を含む乾燥粉末及び乾燥粉末薬剤輸送システム |
WO2013151729A1 (en) | 2012-04-03 | 2013-10-10 | Trustees Of Boston University | Compositions, methods and assays comprising amylin or amlyin analogs for abeta-peptide mediated disorders |
SG11201500218VA (en) | 2012-07-12 | 2015-03-30 | Mannkind Corp | Dry powder drug delivery systems and methods |
US10159644B2 (en) | 2012-10-26 | 2018-12-25 | Mannkind Corporation | Inhalable vaccine compositions and methods |
PL2968443T3 (pl) | 2013-03-15 | 2022-02-07 | Protagonist Therapeutics, Inc. | Analogi hepcydyny i ich zastosowania |
WO2014144895A1 (en) | 2013-03-15 | 2014-09-18 | Mannkind Corporation | Microcrystalline diketopiperazine compositions and methods |
AU2014290438B2 (en) | 2013-07-18 | 2019-11-07 | Mannkind Corporation | Heat-stable dry powder pharmaceutical compositions and methods |
WO2015021064A1 (en) | 2013-08-05 | 2015-02-12 | Mannkind Corporation | Insufflation apparatus and methods |
US10307464B2 (en) | 2014-03-28 | 2019-06-04 | Mannkind Corporation | Use of ultrarapid acting insulin |
KR20230036156A (ko) | 2014-05-16 | 2023-03-14 | 프로타고니스트 테라퓨틱스, 인코포레이티드 | α4β7 인테그린 티오에테르 펩티드 길항제 |
RU2736637C9 (ru) | 2014-07-17 | 2021-02-08 | Протагонист Терепьютикс, Инк. | Пептидные ингибиторы рецептора интерлейкина-23 для перорального приема и их применение для лечения воспалительных заболеваний кишечника |
AU2015328002A1 (en) | 2014-10-01 | 2017-04-27 | Protagonist Therapeutics, Inc. | Novel alpha4beta7 peptide monomer and dimer antagonists |
US10301371B2 (en) | 2014-10-01 | 2019-05-28 | Protagonist Therapeutics, Inc. | Cyclic monomer and dimer peptides having integrin antagonist activity |
US10561806B2 (en) | 2014-10-02 | 2020-02-18 | Mannkind Corporation | Mouthpiece cover for an inhaler |
KR101669140B1 (ko) * | 2015-04-28 | 2016-10-26 | (주)케어젠 | 항비만 및 항당뇨 효능을 갖는 펩타이드 및 이의 용도 |
US10787490B2 (en) | 2015-07-15 | 2020-09-29 | Protaganist Therapeutics, Inc. | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases |
CA3009834A1 (en) | 2015-12-30 | 2017-07-06 | Protagonist Therapeutics, Inc. | Analogues of hepcidin mimetics with improved in vivo half lives |
US10278957B2 (en) | 2017-09-11 | 2019-05-07 | Protagonist Therapeutics, Inc. | Opioid agonist peptides and uses thereof |
EP3749345A4 (de) | 2018-02-08 | 2022-04-06 | Protagonist Therapeutics, Inc. | Konjugierte hepcidin-mimetika |
EP3997105A4 (de) | 2019-07-10 | 2023-09-13 | Protagonist Therapeutics, Inc. | Peptidinhibitoren des interleukin-23-rezeptors und deren verwendung zur behandlung entzündlicher erkrankungen |
IL294680A (en) | 2020-01-15 | 2022-09-01 | Janssen Biotech Inc | Peptide inhibitors of the interleukin-23 receptor and their use for the treatment of inflammatory diseases |
KR20220141808A (ko) | 2020-01-15 | 2022-10-20 | 얀센 바이오테크 인코포레이티드 | 인터루킨-23 수용체의 펩티드 억제제 및 염증성 질환을 치료하기 위한 이의 용도 |
PE20240631A1 (es) | 2020-11-20 | 2024-03-26 | Janssen Pharmaceutica Nv | Composiciones de inhibidores peptidicos del receptor de interleucina-23 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8720115D0 (en) * | 1987-08-26 | 1987-09-30 | Cooper G J S | Treatment of diabetes mellitus |
GB8709871D0 (en) * | 1987-04-27 | 1987-06-03 | Turner R C | Peptides |
US5814600A (en) * | 1991-05-24 | 1998-09-29 | Amylin Pharmaceuticals Inc. | Method and composition for treatment of insulin requiring mammals |
CA2120131A1 (en) * | 1991-09-27 | 1994-05-11 | Robert A. Murgita | Expression and purification of cloned human alpha-fetoprotein |
US5965528A (en) * | 1991-09-27 | 1999-10-12 | Mcgill University | Recombinant human alph-fetoprotein as an immunosuppressive agent |
JPH07509008A (ja) * | 1993-05-12 | 1995-10-05 | ユニバーシティ・オブ・シンシナティ | アミリン・アンタゴニストおよびアゴニスト |
US5625032A (en) * | 1993-07-21 | 1997-04-29 | Amylin Pharmaceuticals, Inc. | Selective amylin antagonist peptides and uses therefor |
US6143718A (en) * | 1995-06-07 | 2000-11-07 | Amylin Pharmaceuticals, Inc. | Treatment of Type II diabetes mellutis with amylin agonists |
-
1998
- 1998-08-21 US US09/138,056 patent/US6087334A/en not_active Expired - Lifetime
-
1999
- 1999-08-09 EP EP99939073A patent/EP1104438B1/de not_active Expired - Lifetime
- 1999-08-09 ES ES99939073T patent/ES2283127T3/es not_active Expired - Lifetime
- 1999-08-09 WO PCT/US1999/017918 patent/WO2000011029A2/en active IP Right Grant
- 1999-08-09 AT AT99939073T patent/ATE354590T1/de not_active IP Right Cessation
- 1999-08-09 AU AU53430/99A patent/AU766545B2/en not_active Ceased
- 1999-08-09 JP JP2000566301A patent/JP2002523424A/ja active Pending
- 1999-08-09 CA CA2337971A patent/CA2337971C/en not_active Expired - Fee Related
- 1999-08-09 DE DE69935229T patent/DE69935229T2/de not_active Expired - Lifetime
-
2001
- 2001-12-06 HK HK01108592A patent/HK1038025A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
CA2337971C (en) | 2011-04-26 |
CA2337971A1 (en) | 2000-03-02 |
EP1104438B1 (de) | 2007-02-21 |
ATE354590T1 (de) | 2007-03-15 |
AU766545B2 (en) | 2003-10-16 |
WO2000011029A2 (en) | 2000-03-02 |
WO2000011029A3 (en) | 2000-06-22 |
DE69935229D1 (de) | 2007-04-05 |
US6087334A (en) | 2000-07-11 |
AU5343099A (en) | 2000-03-14 |
ES2283127T3 (es) | 2007-10-16 |
JP2002523424A (ja) | 2002-07-30 |
DE69935229T2 (de) | 2007-11-08 |
EP1104438A2 (de) | 2001-06-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1038025A1 (en) | Novel anti-diabetic peptides | |
CA2116478A1 (en) | Prolonged delivery of peptides | |
IL112112A (en) | Peptides with growth hormone releasing properties and pharmaceutical compositions containing them | |
MY136926A (en) | Glucokinase activators | |
GEP20074144B (en) | Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function | |
JO2034B1 (en) | Isotopes of the hormone peptide its uses and the chemical compounds it contains | |
ZA834051B (en) | Mammalian pgrf. | |
BG103264A (en) | Substituted n-[(aminoiminomethyl or aminomethyl)phenyl]propyl amides | |
BG104060A (en) | Diabetes treatment with thiazolyidindion and methformine | |
YU41199A (sh) | Hinoksalindioni | |
BG104135A (en) | Diabetes treatment with thiazolydindion, a form increasing the insulin and biguanide secretion | |
IL115966A (en) | Neuroprotective pharmaceutical compositions comprising GDNF | |
ATE238689T1 (de) | ZUSAMMENSETZUNG DIE EINEN ALPHA-AMYLASE INHIBITOR UND MINDESTENS EINE PHYSIOLOGISCH AKZEPTABELE KOMPONENTE, DER DIE INTESTINALE ABSORPTION VON ßFAST SUGARSß REDUZIEREN KANN, ENTHÄLT | |
EP1053001A4 (de) | Neue verbindungen mit gemischter amylin aktivität | |
BG104139A (en) | Diabetes treatment with thizolidindion and sulphonylurea | |
BG104062A (en) | Treatment of diabetes with thiazolidindion, stimulant of insulin secretion and alpha-glucosidase inhibitor | |
GR3034549T3 (en) | Anhydrous composition comprising lactulose | |
CA2117209A1 (en) | 2-substituted-5-chlorimidazoles | |
CA2383056A1 (en) | Novel composition and emulsifier | |
JO1711B1 (en) | Therapeutic agents | |
NO950114L (no) | Amylin-antagonister og agonister | |
UA15356A (uk) | Композиція для одержаhhя вогhезахисhого покриття | |
UA88862C2 (en) | Glucagon-like peptide-1 analogs |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20100809 |